Back to mobile site

MedX Health seeks final 30-day extension for convertible note placement

April 15, 2026 7:00 AM EDT

MedX Health Corp. (TSX-V: MDX) has applied to the TSX Venture Exchange for a final 30-day extension to May 15, 2026, to complete additional closings of its non-brokered private placement of Series IV Convertible Loan Notes.



The company completed an initial closing on February 27, 2026, raising $2.7 million through the issuance of Series IV Notes. The extension would allow MedX to raise up to an additional $2.3 million through further closings.



The Series IV Notes carry a 6% annual interest rate paid quarterly and mature on December 31, 2028. Note holders may convert their securities into units at $0.10 per unit until maturity. Each unit consists of one common share and half of a share purchase warrant, with each full warrant exercisable at $0.125 until the maturity date.



Holders of Series I Convertible Loan Notes, which matured on December 31, 2025, may exchange their notes for Series IV Notes. The Series I Notes had a conversion price of $0.14 and warrant exercise price of $0.20.



Qualified agents will receive a 6% cash commission on gross proceeds from subscribers they introduce, plus agent's warrants equal to 6% of those subscriptions. The agent's warrants are exercisable at CAD$0.10 for units comprising one common share and half of a share purchase warrant exercisable at CAD$0.125.



The company stated that certain insiders may participate in the placement, subject to regulatory exemptions. Proceeds will fund redemption of unconverted Series I Notes, development of the company's SIAscopy technology and DermSecure telemedicine platform, expansion into occupational health markets, and general corporate purposes.



MedX Health operates a medical technology platform focused on non-invasive skin screening and teledermatology through proprietary imaging technology cleared for use in multiple jurisdictions including Canada, the United States, and the European Union.


You May Also Be Interested In





Related Categories

Equity Offerings

Related Entities

Definitive Agreement, FDA